75. クッシング病 Cushing disease Clinical trials / Disease details

臨床試験数 : 205 / 薬物数 : 176 - (DrugBank : 45) / 標的遺伝子数 : 61 - 標的パスウェイ数 : 127

33 trials found

diseases per page:

Showing 1 to 10 of 33 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04339751 (ClinicalTrials.gov)	March 22, 2023	8/4/2020	Effect of Vorinostat on ACTH Producing Pituitary Adenomas in Cushing s Disease	The Effect of Vorinostat on ACTH Producing Pituitary Adenomas in Cushing's Disease	Cushing's Disease	Drug: Vorinostat	National Institute of Neurological Disorders and Stroke (NINDS)	NULL	Recruiting	18 Years	N/A	All	22	Phase 2	United States
2	NCT04569591 (ClinicalTrials.gov)	March 22, 2023	29/9/2020	Corticotrophin-releasing Hormone (CRH) Stimulation for 18F-FDG-PET Detection of Pituitary Adenoma in ...	Corticotrophin-Releasing Hormone (CRH) Stimulation for 18F-FDG-PET Detection of Pituitary Adenoma in ...	Cushing's Disease;Pituitary Adenoma	Drug: Acthrel	National Institute of Neurological Disorders and Stroke (NINDS)	NULL	Not yet recruiting	8 Years	N/A	All	22	N/A	United States
3	EUCTR2021-006184-19-BG (EUCTR)	22/06/2022	31/05/2022	Study of SPI-62 in Patients with Adrenocorticotropic Hormone-dependent Cushing’s Syndrome	SPI-62 as a Treatment for Adrenocorticotropic Hormone-dependent Cushing’s Syndrome	Cushing’s Syndrome MedDRA version: 20.1;Level: PT;Classification code 10035109;Term: Pituitary-depen ...	Product Name: SPI-62 Product Code: SPI-62 INN or Proposed INN: Not applicable Other descriptive name: 1 ...	Sparrow Pharmaceuticals, Inc.	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	26	Phase 2	United States;Romania;Bulgaria
4	NCT05307328 (ClinicalTrials.gov)	March 1, 2022	23/3/2022	SPI-62 as a Treatment for Adrenocorticotropic Hormone-dependent Cushing's Syndrome	SPI-62 as a Treatment for Adrenocorticotropic Hormone-dependent Cushing's Syndrome	Cushing's Syndrome I;Cushing Disease Due to Increased ACTHSecretion;Cortisol Excess;Cortisol; Hypers ...	Drug: SPI-62;Drug: Placebo	Sparrow Pharmaceuticals	NULL	Recruiting	18 Years	N/A	All	26	Phase 2	Romania;Bulgaria;United States
5	EUCTR2019-004019-29-IT (EUCTR)	15/07/2021	07/10/2020	Italian study to evaluate the efficacy of retinoic acid and cabergoline therapy in combination in Cu ...	Medical combination therapy with retinoic acid and cabergoline in ACTH-secreting pituitary adenoma: ...	Cushing's disease in patients in whom pituitary surgery has not been curative or in situations where ...	Trade Name: Dostinex Product Name: Cabergolina Product Code: [G02CB03] INN or Proposed INN: CABERGOLINA ...	Dipartimento di Medicina-DIMED, università di Padova	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	60	Phase 2	Italy
6	ChiCTR-OPC-17011664	2017-08-01	2017-06-14	A single center clinical study of EGFR/HER2 targeted inhibitor Lapatinib in the treatment of refract ...	A single center clinical study of EGFR/HER2 targeted inhibitor Lapatinib in the treatment of refract ...	Pituitary ACTH-secreting adenoma	Treatment group:lapatinib;	Peking Union Medical College Hospital	NULL	Pending	18	75	Both	Treatment group:30;		China
7	EUCTR2013-000267-84-PL (EUCTR)	05/02/2016	16/12/2015	Study to roll over patients who have completed a study with pasireotide and benefit from the study t ...	An open label, multicenter pasireotide roll over protocol for patients who have completed a previous ...	Cushing's diseaseAcromegalyNeuroendocrine tumorsPituitary tumorsEctopic ACTHsecreting (EAS) tumorsDu ...	Trade Name: Signifor Product Name: pasireotide Product Code: SOM230 INN or Proposed INN: pasireotide Oth ...	Novartis Pharma Services AG	NULL	Not Recruiting			Female: yes Male: yes	100	Phase 4	Portugal;United States;Taiwan;Greece;Thailand;Spain;Israel;Russian Federation;Italy;France;Mexico;Ca ...
8	NCT02468193 (ClinicalTrials.gov)	September 24, 2015	8/6/2015	Study of Efficacy and Safety of Osilodrostat in Cushing's Syndrome	A Phase II, Open-label, Dose Titration, Multi-center Study to Assess the Safety/Tolerability and Eff ...	Cushing's Syndrome;Ectopic Corticotropin Syndrome;Adrenal Adenoma;Adrenal Carcinoma;AIMAH;PPNAD	Drug: Osilodrostat	Novartis Pharmaceuticals	NULL	Completed	18 Years	85 Years	All	9	Phase 2	Japan
9	EUCTR2013-002063-26-IT (EUCTR)	08/09/2013	23/07/2013	A trial with Metyrapone in Cushing's syndrome	A prospective open-label Phase 2 study of METYRAPONE as a preoperative treatment in patients with AC ...	Cushing's syndrome;Therapeutic area: Diseases [C] - Hormonal diseases [C19]	Trade Name: Matyrapone Product Name: Metyrapone Product Code: Metyrapone	S.C.D.U. MEDICINA INTERNA 1 Ospedale San Luigi Orbassano	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	15	Phase 2	Italy
10	EUCTR2013-000267-84-FR (EUCTR)	07/08/2013	23/09/2015	An open label, multicenter pasireotide roll over protocol for patients who have completed a previous ...	An open label, multicenter pasireotide roll over protocol for patients who have completed a previous ...	Cushing’s diseaseAcromegalyNeuroendocrine tumorsPituitary tumorsEctopic ACTHsecreting (EAS) tumorsDu ...	Trade Name: Signifor Product Name: pasireotide Product Code: SOM230 INN or Proposed INN: pasireotide Tra ...	Novartis Pharma Services AG	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	100		United States;Greece;Spain;Thailand;Russian Federation;Israel;Italy;France;Mexico;Canada;Belgium;Bra ...

First Previous1 2 3 4Next Last